Found 2 clinical trials
Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis
Patients will be annually followed to assess the influence of personalized dosing on John Cunningham virus (JCV) conversion, JCV index, incidence of progressive multifocal leukoencephalopathy and treatment satisfaction and quality of life. The influence of personalized dosing on pharmacokinetics will be monitored.
- 0 views
- 16 Feb, 2024
- 15 locations
The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project
There is currently lack of collaborative data on the epidemiology, clinicopathologic features and treatment outcome of newly diagnosed and relapsed APL in Asia. In addition, there is lack of data comparing oral- As2O3-based regimens with other treatment approaches, including intravenous As2O3,in the frontline or relapsed setting. With the long-term data …
- 0 views
- 16 Feb, 2024
- 1 location